A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
| Autor: | Takeda, Masayuki, Shimokawa, Mototsugu, Nakamura, Atsushi, Nosaki, Kaname, Watanabe, Yasutaka, Kato, Terufumi, Hayakawa, Daisuke, Tanaka, Hiroshi, Takahashi, Toshiaki, Oki, Masahide, Tachihara, Motoko, Fujimoto, Daichi, Hayashi, Hidetoshi, Yamaguchi, Kakuhiro, Yamamoto, Shoichiro, Iwama, Eiji, Azuma, Koichi, Hasegawa, Kazuo, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko |
|---|---|
| Zdroj: | In Lung Cancer March 2023 177:44-50 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect